Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharming Group N.V.

9.13
-0.0151-0.17%
Post-market: 9.12-0.0149-0.16%16:05 EDT
Volume:2.36K
Turnover:21.70K
Market Cap:624.76M
PE:-42.94
High:9.34
Open:9.33
Low:9.13
Close:9.15
Loading ...

Stock Track | Pharming Group Soars 12.78% on Strong Q1 Results and Raised 2025 Guidance

Stock Track
·
08 May

Pharming Q1 EPS $(0.22) Misses $(0.01) Estimate, Sales $79.10M Beat $67.73M Estimate

Benzinga
·
08 May

Pharming Group NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Pharming Group 2025 Raises Total Revenue Guidance To $325M-$340M (Prior $315M-$335M) vs. $324.3M Est.

Benzinga
·
08 May

Pharming Q1 Sales $79.10M Beat $67.73M Estimate, Adj. Net Loss $7.1M

Benzinga
·
08 May

Press Release: Pharming Group reports first quarter 2025 financial results and provides business update

Dow Jones
·
08 May

Pharming Group NV expected to post a loss of 1 cent a share - Earnings Preview

Reuters
·
06 May

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

GlobeNewswire
·
30 Apr

SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock?

Zacks
·
25 Apr

Pharming Group to report first quarter 2025 financial results on May 8

GlobeNewswire
·
24 Apr

Pharming announces positive recommendation from NICE for Joenja

TIPRANKS
·
23 Apr

Pharming Group Gets Positive Recommendation in UK for Immunodeficiency Treatment

MT Newswires Live
·
23 Apr

European Opportunities: 3 Penny Stocks With Market Caps Larger Than €10M

Simply Wall St.
·
15 Apr

Exploring Three High Growth Tech Stocks In Europe

Simply Wall St.
·
08 Apr

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

GlobeNewswire
·
03 Apr

Pharming Group to participate in April investor conferences

GlobeNewswire
·
28 Mar

Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

GlobeNewswire
·
20 Mar

Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

Pharming Group (PHGUF) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com
·
14 Mar